IDT Australia : Investor Update - mRNA

ersonal use only

IDT AUSTRALIA LIMITED

Investor Update - mRNA Initiatives

13 December 2021

Disclaimer

This presentation is for general information purposes only.

onlyThis presentation does not provide recommendations or opinions in relation to specific investments or securities. This presentation has been prepared in good faith and with reasonable care. Neither IDT nor any other person makes any representation or warranty, express or implied, as to the accuracy, reliability, reasonableness or completeness of the contents of this presentation (including any projections, forecasts, estimates, prospects and returns), and any omissions from this presentation. To the maximum extent permitted by law, IDT and its respective directors, officers, employees and advisers disclaim and exclude all liability for any loss or damage (whether or not foreseeable) suffered or incurred by any person acting on any information (including any projections, forecasts, estimates, prospects and returns)

useprovided in, or omitted from, this presentation or any other written or oral information provided by or on behalf of IDT.

It is not intended that this presentation be relied upon and the information in this presentation does not take into account your financial objectives, situations or needs. Investors should consult with their own legal, tax, business and/or financial advisers in connection with any investment decision.

All numbers are as at 30 June 2021 unless otherwise stated. Numbers may not add up due to rounding.

ersonalAll data presented in this document reflects the current views of the Company with respect to future events. Forward- looking statements are subject to a variety of risks, uncertainties and assumptions relating to the operations, results of

operations, growth strategy and liquidity of the Company. Forward looking statements are also subject to external matters outside the control of the Company.

The release of this presentation has been authorised by IDT's Board of Directors.

2

Executive Summary

only
• Founded in 1975, IDT Australia Limited is a TGA and FDA inspected and approved
	pharmaceutical contract manufacturing organisation located in the eastern suburbs of
	Melbourne

• Situated within IDT's 12,000m2 manufacturing site is the Company's flagship sterile

use	manufacturing facility
• IDT's sterile manufacturing facility received its sterile manufacturing licence from the TGA
	(Sept `21) and has now (Nov `21) manufactured Australia's first cGMP mRNA drug product,
	being the Monash/Doherty COVID-19 receptor binding domain vaccine candidate

• A key component of the Company's stated goals for FY`22 and beyond is for IDT to

ersonal3

become Australia's cGMP mRNA Manufacturing Hub of Excellence

Sterile Manufacturing:

only• use•

•

ersonal•

Sterile Readiness Agreement Finalised Site Licence Secured

Sterile Facility Ready To Accept Contract Development and Manufacturing Content

IDT finalised a Sterile Readiness Letter Agreement with the Australian Government

Department of Health (Aug `21)

IDT's flagship sterile manufacturing facility in Boronia brought into a state of sterile readiness so that IDT can use the facility to potentially provide assistance to the Government in connection with the Government's rollout of COVID-19 vaccines in Australia (Mar-Sept `21)

Sterile Manufacturing Licence (the Company's first ever sterile licence) secured from the

Therapeutic Goods Administration (late Sept `21)

IDT's sterile manufacturing facility is now licenced and can be deployed to support a range of sterile contract product development and manufacturing opportunities:

• For the Australian Government, during the Sterile Readiness Letter Agreement exclusivity period; and
• For third parties following the cessation of the Sterile Readiness Letter Agreement exclusivity period

• IDT is the first in Australia to manufacture a cGMP mRNA drug product

• The Monash / Doherty COVID-19vaccine candidate is Australia's first locally developed mRNA COVID-19vaccine candidate; and

Australia's First mRNA Drug Product

• IDT has successfully manufactured an mRNA drug product. This achievement represents two onlyAustralian firsts:

• The Monash / Doherty COVID-19 vaccine candidate is unique in that, unlike all of the usecommercially available COVID-19 vaccines which target the whole spike protein, the Monash / Doherty vaccine targets the Receptor Binding Domain (RBD) a smaller functional sub-unit of

the spike protein

• Monash / Doherty selected this novel approach to focus specifically on the RBD to prevent viral attachment, thereby preventing infection

ersonal• The significance of this achievement is that Australia now has a COVID-19 RBD vaccine candidate which can be modified in response to emerging virus mutations in COVID-19 Variants of Concern (VOC's); and IDT Australia is developing the capabilities to manufacture these mRNA products for the current pandemic and for the future

5